ArriVent moves to take on Rybrevant
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
J&J’s new trispecific play
JNJ-95566692 enters phase 1, with Qilu neck and neck.
A new clinical KRAS degrader
Three private biotechs enter clinical trials, one targeting KRAS.
Rakuten sheds light on its conjugate
The company secures funding to push its lead candidate towards US approval.
Incyte does TGF-beta differently
Four months after yielding first-in-human data INCA33890 enters phase 3.
The month ahead: January’s remaining events
JP Morgan approaches.
FDA red and green lights: December 2025
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
GSK makes haste while Daiichi struggles
Mocertatug rezetecan is starting its first western pivotal trials.
Another in vivo Car speeds into the clinic
PersonGen’s LV009 takes the industry tally of clinical-stage projects to 14.
